Researchers at Washington University School of Medicine in St. Louis received $17 million from the Advanced Research Projects Agency for Health to advance an injectable osteoarthritis treatment toward clinical trials. The funding supports the second phase of a project developing…
Biologics
Platelet-rich plasma and stem cell-based therapies have shown potential to relieve pain and improve function in patients with degenerative disc disease, but clinical evidence remains inconsistent, according to a review in the fall 2026 issue of Vertebral Columns. The review…
Los Angeles-based Keck Medicine of University of Southern California has launched a clinical trial evaluating the safety of an experimental injection and its potential to prevent cartilage deterioration in patients with knee osteoarthritis. The treatment, CX-011, is administered as a…
Regentis Biomaterials is developing GelrinC, a cell-free hydrogel implant for focal knee cartilage defects, which the company said reflects a shift in orthopedics toward earlier structural repair rather than symptom management alone. GelrinC is designed to erode as new cartilage…
Biopharmaceutical company Scholar Rock’s Isembyld treatment was approved by the FDA to treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2-targeted treatment. Isembyld is the…
Advertisement
Regentis Biomaterials has treated 43 of 80 patients in its pivotal U.S. trial evaluating GelrinC, a hydrogel implant for focal articular knee cartilage injuries. The company now expects to complete full enrollment on or around the end of 2026, compared…
Bone Biologics has doubled the number of Australian hospital sites participating in its first-in-human pilot clinical trial of NB1, its bone graft product for spinal fusion. Six hospital sites are now under agreement to participate in the trial. The company…
Researchers at New York City-based Weill Cornell Medicine and Hospital for Special Surgery identified stem cells that give rise to tendons and ligaments and found that their overactivity may contribute to lumbar spinal stenosis. The researchers identified the stem cells…
Tampa, Fla.-based Joseph Spine Institute launched a Regenerative Therapy Center offering autologous adipose-derived cell therapies and platelet-rich plasma for spine and musculoskeletal care. The practice said the center will combine regenerative therapies with spine diagnosis, interventional pain management, sports medicine…
University of California Los Angeles researchers found little evidence supporting the use of six emerging peptides for musculoskeletal treatment, tissue recovery or performance. The researchers reviewed 565 studies examining BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. More than two-thirds of…